Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7983774 | 0.82 | PDCD1 (0.42) | MAPK1FFAR1MAPTKCNN4ALDH1A1 | |
| SCHEMBL11869553 | 0.81 | ALOX5AP (0.43) | KDM4EFFAR1MAPTKCNN4NPC1 | |
| SCHEMBL30094656 | 0.81 | ALOX5AP (0.43) | KDM4EFFAR1MAPTKCNN4NPC1 | |
| SCHEMBL31542585 | 0.81 | MAPT (0.58) | KDM4EMAPK1MAPTNPC1MEN1 | |
| SCHEMBL31391954 | 0.81 | ALOX5AP (0.40) | FFAR1MAPTKCNN4NPC1RAB9A | |
| SCHEMBL5808039 | 0.81 | MAPT (0.58) | KDM4EMAPK1MAPTNPC1MEN1 | |
| SCHEMBL12578542 | 0.81 | ALOX5AP (0.40) | KDM4EFFAR1MAPTKCNN4NPC1 | |
| SCHEMBL10192222 | 0.81 | L3MBTL1 (0.55) | KDM4EFFAR1MAPTMEN1KMT2A | |
| SCHEMBL9781787 | 0.81 | KDM4E (0.40) | KDM4EMAPK1MAPTAPOBEC3GALDH1A1 | |
| SCHEMBL9516642 | 0.78 | L3MBTL1 (0.62) | FFAR1MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220373-A1 | Therapeutic uses of PPAR mediators | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2003-11-27 | — | — | US | disclosed |
| EP-1267874-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | Aventis Pharma Deutschland GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| EP-1030665-A4 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARM PROD INC (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| WO-2001066098-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | AVENTIS PHARMA DEUTSCHLAND GMBH | 2001-09-13 | — | — | WO | disclosed |
| CN-1302206-A | Therapeutic uses of quinoline derivatives | HOECHST MEDICINE PRODUCT CO (US) | 2001-07-04 | — | — | CN | disclosed |
| EP-1030665-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | Aventis Pharmaceuticals Products Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999020275-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| WO-1989004305-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220373-A1 | Therapeutic uses of PPAR mediators | PPARG, PPARA, PPARD | KDM4E 4186/4885MAPK1 2836/4885FFAR1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.